<ul data-eligibleForWebStory="false"><li>B&K Securities initiated coverage on Indegene with a 'hold' rating and projected a 15% upside potential with a target price of Rs 648 apiece.</li><li>Indegene, specializing in life sciences commercialization, is well-placed to benefit from outsourcing trends in the industry, according to B&K Securities.</li><li>The company has experienced judicious growth through acquisitions, scaling from $10 million to $90 million in revenue between 2010–20.</li><li>However, risks for Indegene include overreliance on Africa and Europe, potential drug price reductions, and increasing competition from global capability centers in the biopharma industry.</li></ul>

Indegene Gets B&K's Initiation With 15% Upside Projection

Discover more